Monday, April 27, 2009
MONDAY, April 27 (HealthDay News) -- Diet supplementation with soy protein, vitamin E and selenium did not prevent the development of prostate cancer in men with a precursor prostate condition, according to research presented at the annual meeting of the American Urological Association held April 25 to 30 in Chicago.
Neil E. Fleshner, M.D., of the Ontario Cancer Institute in Canada, and colleagues enrolled 303 men, median age 62.8 years, from 12 Canadian medical centers in a randomized, double-blind placebo-controlled study to test the hypothesis that vitamin E, selenium and soy protein may prevent progression of High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) to prostate cancer. For three years, the study group was given a daily treatment regimen of soy protein (40 gram/daily), vitamin E (800 IU/daily) and selenium (200 microgram/daily), or placebo. Prostate biopsy follow-ups were performed at six, 12, 24 and 36 months, and the study endpoint was time to prostate cancer development.
Invasive prostate cancer eventually developed in 26.4 percent of patients, the researchers discovered. They further noted that, among the cohort receiving the nutritional supplement, the prostate cancer prevention hazard ratio was 1.03. In both treated and control groups, age, weight, prostate-specific antigen and testosterone at baseline were not found to be predictors for prostate cancer development.
"This trial does not support the hypothesis that combination therapy with vitamin E, selenium and soy prevents progression from HGPIN to prostate cancer," the researchers conclude.
Dr. Fleshner reported a relationship with Bioadvantex Pharma Inc., a maker of prostate medications.
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.